Jacobio Pharma has entered into a global exclusive license agreement with AstraZeneca for the development and commercialization of JAB-23E73, a proprietary Pan-KRAS inhibitor designed to target multiple KRAS mutation subtypes.

Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China. In the Chinese market, both companies will collaborate on joint development and commercialization efforts.

JAB-23E73 was developed using Jacobio’s induced allosteric drug discovery platform. As a Pan-KRAS inhibitor, it aims to treat various KRAS-mutated cancers—including lung, colorectal, and pancreatic—which have historically been difficult to target.

"This collaboration marks a significant step forward as we bring our world-class programs to the global stage and maximize the value of our R&D innovation," said Dr. Yinxiang Wang, Chairman and Co-CEO of Jacobio Pharma.

Matt Hellmann, Senior Vice President of Oncology R&D at AstraZeneca, added, "By advancing KRAS inhibitors like JAB-23E73... we aim to accelerate the development of new treatment regimens that have the potential to transform outcomes for patients."
The partnership combines Jacobio’s specialized R&D with AstraZeneca’s global oncology leadership to address the significant unmet needs of patients with KRAS-driven tumors.